Cancer bio-immunotherapy XVI annual NIBIT-(Italian Network for Tumor Biotherapy) meeting, October 11-13 2018, Milan, Italy

Cancer Immunol Immunother. 2020 Jun;69(6):1141-1151. doi: 10.1007/s00262-020-02502-1. Epub 2020 Feb 6.

¹ Unit of Cellular Immunology, IRCCS Ospedale San Raffaele, Milan, Italy.
² Unit of Immuno-Biotherapy of Melanoma and Solid Tumors, IRCCS Ospedale San Raffaele, Milan, Italy.
³ Unit of Experimental Immunology, IRCCS Ospedale San Raffaele, Milan, Italy.
⁴ Unit of Immunotherapy and Anticancer Innovative Therapeutics, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
⁵ Unit of Tumor Immunology, IRCCS Ospedale San Raffaele, Milan, Italy.
⁶ Unit of Molecular Immunology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
⁷ Department of Inflammation and Immunology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
⁸ University of Padua, Padua, Italy.
⁹ Oncology Unit, ASST Valle Olona, Ospedale di Circolo di Busto Arsizio, Busto Arsizio, Italy.
¹⁰ Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy.
¹¹ European Institute of Oncology IRCCS, Milan, Italy.
¹² Department of Haematology, Oncology and Molecular Medicine, Istituto Superiore Di Sanità, Rome, Italy.
¹³ Unit of Immuno-Biotherapy of Melanoma and Solid Tumors, IRCCS Ospedale San Raffaele, Milan, Italy. russo.vincenzo@hsr.it.

No abstract available

Keywords: Adoptive immunotherapy; Cancer vaccines; Checkpoint blockade agents; Immunotherapy; NIBIT; Targeted therapies.

Publication types